Exhibit 99.1
Exhibit 99.1
MEDITE Cancer Diagnostics Reports Appointments of New Chairman of
the Board and Chief Executive Officer
Orlando, FL, November 7, 2017 - MEDITE Cancer
Diagnostics, Inc. (OTCQB: MDIT, the “Company”),
specializing in the development, manufacturing and marketing of
molecular biomarkers and premium medical devices for detection,
risk assessment and diagnosis of cancer and precancerous
conditions, today announced that the Board of Directors has
appointed Austin Lewis as Chairman and Stephen Von Rump as Chief
Executive Officer, both appointments effective immediately. On
November 5, 2017, David Patterson, the previous CEO and Chairman
notified the Board that he is retiring as the Company’s Chief
Executive Officer, and is resigning from his positions of Chairman
of the Board and Board member, effective immediately. Mr. Lewis
continues in his role as a Director, while Mr. Von Rump was
previously the Chief Commercialization and Strategy Officer for the
Company.
“With
the recent completion of financing, the Company enters a new phase
in its growth and execution plans,” said Austin Lewis,
Chairman of MEDITE. “We believe these changes, including the
appointment of Stephen Von Rump as CEO align the Company’s
leadership to the tasks in front of us now. The Board of Directors
thanks David Patterson for his leadership, commitment and
contributions that have brought the Company to where it is
today.”
“I
welcome the opportunity to serve the Company in this new
role,” added Stephen Von Rump, CEO of MEDITE. “The
market potential is exciting, particularly for the new products
that we will introduce over the coming year, and I am fortunate to
lead an organization that is deeply committed to our
success.”
About MEDITE Cancer Diagnostics, Inc.
MEDITE
Cancer Diagnostics, Inc. is a global company that specializes in
the development, engineering, manufacturing and marketing of
premium medical devices and consumables for detection, risk
assessment and diagnosis of cancer and related diseases. The
Company offers a comprehensive suite of innovative products, both
histopathology (tissue biopsy) and cytopathology (liquid cell)
based, that target large markets and cover the complete laboratory
process from biopsy to finished slide, for screening and diagnostic
tests. MEDITE’s current and future products assist in the
early diagnoses of cancer, with a target result of contributing to
more lives saved at lower costs. MEDITE’s products are
currently being distributed in over 80 countries
worldwide.
Forward Looking Statement
This
press release may include forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
regarding future operating performance, events, trends and plans.
All statements other than statements of historical fact contained
herein, including, without limitation, statements regarding our
future financial position, business strategy, implementation of the
strategic initiatives relative to the refinancing transaction
referenced above, budgets, projected revenues and costs, and plans
and objectives of management for future operations, are
forward-looking statements. Forward-looking statements generally
can be identified by the use of forward-looking terminology such as
“may,” “will,” “expects,”
“intends,” “plans,” “projects,”
“estimates,” “anticipates,” or
“believes” or the negative thereof or any variation
thereon or similar terminology or expressions. We have based these
forward-looking statements on our current expectations and
projections about future events. These forward-looking statements
are not guarantees and are subject to known and unknown risks,
uncertainties and assumptions about us that may cause our actual
results, levels of activity, performance or achievements to be
materially different from any future results, levels of activity,
performance or achievements expressed or implied by such
forward-looking statements.
Important
factors that could cause our actual results to be materially
different than those expressed in our forward-looking statements
include: our ability to raise capital; our ability to retain key
employees; our ability to engage third party distributors to sell
our products; economic conditions; technological advances in the
medical field; demand and market acceptance risks for new and
existing products, technologies, and healthcare services; the
impact of competitive products and pricing; US and international
regulatory, trade, and tax policies; product development risks,
including technological difficulties; ability to enforce patents;
and foreseeable and unforeseeable foreign regulatory and
commercialization factors, our ability to develop new products and
respond to technological changes in the markets in which we
compete, our ability to obtain government approvals of our
products, our ability to market our products, and changes in
third-party reimbursement procedures.
Readers
are cautioned not to place undue reliance on our forward-looking
statements, as they speak only as of the date made. Such statements
are not guarantees of future performance or events and we undertake
no obligation to disclose any revision to these forward-looking
statements to reflect events or circumstances occurring after the
date hereof.
Investor Contacts:
Steve
Silver/Valter Pinto
KCSA
Strategic Communications
Phone:
212-896-1220/212-896-1254
medite@kcsa.com
